NADAC acquisition cost data for OPIUM TINCTURE 10 MG/ML. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 42799021701 | $2.96 | 2022-09-21 | Rx |
| 62559015304 | $2.96 | 2022-09-21 | Rx |
| 42799021701 | $2.96 | 2022-09-21 | Rx |
| 62559015304 | $2.96 | 2022-09-21 | Rx |
| 42799021701 | $2.96 | 2022-09-21 | Rx |
| 62559015304 | $2.96 | 2022-09-21 | Rx |
| 42799021701 | $2.96 | 2022-09-21 | Rx |
| 62559015304 | $2.96 | 2022-09-21 | Rx |
| 42799021701 | $2.96 | 2022-09-21 | Rx |
| 62559015304 | $2.96 | 2022-09-21 | Rx |
Generic: Opium Tincture | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $5.2M | 11,808 | 2,865 | $3.78 |
| 2020 | $4.9M | 12,202 | 2,926 | $3.57 |
| 2021 | $4.5M | 11,957 | 2,865 | $3.46 |
| 2022 | $4.5M | 11,302 | 2,677 | $3.57 |
| 2023 | $4.2M | 10,625 | 2,582 | $3.68 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $518.7K | 1,203 | 342 |
| New York | $340.1K | 934 | 232 |
| Texas | $297.7K | 485 | 154 |
| Massachusetts | $260.0K | 819 | 161 |
| Missouri | $200.5K | 639 | 128 |
| Indiana | $180.2K | 521 | 134 |
| Florida | $152.2K | 326 | 118 |
| Illinois | $147.8K | 382 | 95 |
| Wisconsin | $140.8K | 402 | 80 |
| Ohio | $134.2K | 406 | 94 |
| Oregon | $133.3K | 277 | 67 |
| Pennsylvania | $127.8K | 380 | 97 |
| Michigan | $117.5K | 290 | 78 |
| Arizona | $106.1K | 242 | 55 |
| Colorado | $101.2K | 185 | 62 |
| Minnesota | $97.0K | 262 | 73 |
| Maryland | $88.8K | 167 | 49 |
| Washington | $82.7K | 228 | 71 |
| Connecticut | $81.7K | 190 | 53 |
| New Jersey | $78.5K | 262 | 71 |
| North Carolina | $78.3K | 222 | 58 |
| Georgia | $67.9K | 217 | 61 |
| Kentucky | $64.4K | 80 | 18 |
| New Hampshire | $64.1K | 96 | 25 |
| Tennessee | $50.8K | 184 | 44 |
| Kansas | $39.7K | 128 | 39 |
| Delaware | $33.8K | 77 | 13 |
| Virginia | $31.3K | 83 | 30 |
| Idaho | $28.4K | 52 | 14 |
| Montana | $28.2K | 46 | 14 |
| District of Columbia | $25.1K | 40 | 13 |
| New Mexico | $22.3K | 29 | N/A |
| Oklahoma | $21.2K | 77 | 13 |
| South Dakota | $20.1K | 17 | N/A |
| Rhode Island | $19.7K | 77 | 14 |
| Maine | $19.6K | 66 | 13 |
| Iowa | $18.9K | 52 | 13 |
| Louisiana | $15.5K | 47 | 22 |
| West Virginia | $15.2K | 46 | N/A |
| Utah | $14.5K | 63 | 16 |
| South Carolina | $12.4K | 49 | 17 |
| Nebraska | $12.3K | 31 | 11 |
| Vermont | $11.5K | 47 | 11 |
| North Dakota | $10.5K | 33 | N/A |
| Wyoming | $8.8K | 41 | N/A |
| Alabama | $7.9K | 48 | N/A |
| Arkansas | $7.7K | 16 | N/A |
| Nevada | $5.8K | 28 | N/A |
| Hawaii | $3.3K | 16 | N/A |
| Mississippi | $2.8K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.